Overview

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

Status:
Completed

Trial end date:
2016-05-05

Target enrollment:

Participant gender:

Summary

The main objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after end of treatment (Day 40 or Day 55).

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Europe Ltd.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Fidaxomicin
Vancomycin